Synlogic, Inc. (SYBX) |
1.855 -0.025 (-1.33%) 04-25 09:54 |
Open: | 1.855 |
High: | 1.855 |
Low: | 1.855 |
Volume: | 359 |
Market Cap: | 22(M) |
PE Ratio: | -0.21 |
Exchange: | NASDAQ Global Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.29 |
Resistance 1: | 1.96 |
Pivot price: | 1.81 |
Support 1: | 1.80 |
Support 2: | 1.70 |
52w High: | 5.708 |
52w Low: | 0.234 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
EPS | -53200000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 478.785 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -384.29 |
Return on Assets (ttm) | -37.0 |
Return on Equity (ttm) | -91.5 |
Sun, 21 Apr 2024
Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies Canada
Tue, 19 Mar 2024
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Tue, 19 Mar 2024
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
Tue, 20 Feb 2024
Synlogic Enacts Shareholder Rights Plan for Equitable Control - TipRanks.com - TipRanks
Fri, 09 Feb 2024
Synlogic shares downgraded after trial discontinuation By Investing.com - Investing.com
Fri, 09 Feb 2024
Why Is Synlogic (SYBX) Stock Down 55% Today? - InvestorPlace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |